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A Rare Nonsense Mutation in the 
Glucokinase Regulator Gene Is Associated 
With a Rapidly Progressive Clinical Form 
of Nonalcoholic Steatohepatitis
Carlos J. Pirola,1,2  Diego Flichman,3 Hernán Dopazo,4 Tomas Fernández Gianotti,2 Julio San Martino,5 Cristian Rohr,4  
Martin Garaycoechea,6 Carla Gazzi,7 Gustavo O. Castaño8, and Silvia Sookoian 1,9
We report on the presence of a rare nonsense mutation (rs149847328, p.Arg227Ter) in the glucokinase regulator (GCKR) 
gene in an adult patient with nonalcoholic fatty liver disease (NAFLD), morbid obesity, and type 2 diabetes; this patient 
developed a progressive histological form of the disease. Analysis of paired (5 years apart) liver biopsies (at baseline and fol-
low-up) showed progression of simple steatosis to severe nonalcoholic steatohepatitis and cirrhosis. Study design involved an 
initial exploration that consisted of deep sequencing of 14 chromosomal regions in 96 individuals (64 of whom were patients 
with NAFLD who were diagnosed by liver biopsy that showed the full spectrum of histological severity). We further per-
formed a replication study to explore the presence of rs149847328 that included a sample of 517 unrelated individuals in a 
case-control study (n = 390), including patients who were morbidly obese (n = 127). Exploration of sequence variation by 
next-generation sequencing of exons, exon–intron boundaries, and 5′ and 3′ untranslated regions of 14 genomic loci that 
encode metabolic enzymes of the tricarboxylic acid cycle revealed the presence of heterozygosity for the p.Arg227Ter muta-
tion, the frequency of which is 0.0003963 (4:10,000; Exome Aggregation Consortium database). GCKR protein expression 
was markedly decreased in the liver of the affected patient compared with patients with NAFLD who carry the wild-type 
allele. Sequencing of the same 14 genomic loci in 95 individuals failed to reveal the rare mutation. The rarity of p.Arg227Ter 
was confirmed in a more extensive screening. Conclusion: While rare variants/mutations are difficult to detect in even rea-
sonably large samples (frequency of the mutant allele of p.Arg227Ter was ~1:1,000 in our data set), the presence of this muta-
tion should be suspected as potentially associated with NAFLD, particularly in young adults at the extreme of histological 
phenotypes. (Hepatology Communications 2018;2:1030-1036)
Nonalcoholic fatty liver disease (NAFLD) is a complex polygenic and multifactorial disease, the risk and course of which are determined 
by the interactions of a large, although not yet identi-
fied, collection of variants and environmental factors. 
Current knowledge indicates that genetic predisposi-
tion to NAFLD is partially explained by common (fre-
quent) variants of genes involved in the regulation of 
metabolic pathways, including patatin-like phospholi-
pase domain containing 3 (PNPLA3), transmembrane 
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6 superfamily member 2 (TM6SF2), and glucokinase 
regulator (GCKR). Variants in these loci (rs738409,(1) 
rs58542926,(2) and rs780094(3,4) explain a modest frac-
tion of the genetic variance in the manifestation of this 
disease. For example, summarized evidence suggests 
that the rs738409 variant is associated with a ~3.5-
fold risk of NAFLD and nonalcoholic steatohepa-
titis (NASH)(1); carrying the T allele of rs58542926 
imposes a ~2.1-fold chance of having NAFLD(2); and 
the rs780094 variant of GCKR is associated with a 
~1.2-fold higher risk of NAFLD.(4) Variants in addi-
tional loci, including a missense (p.Gly17Glu, rs641738 
C/T) variant in exon 1 of transmembrane channel-like 
4 (TMC4)/intergenic downstream of membrane bound 
O-acyltransferase domain containing 7 (MBOAT7) 
has been associated with a modest risk of developing 
NAFLD and NASH.(5) However, this association 
could not be replicated in other populations around 
the world.(6‒10) Finally, recent findings have shown that 
a splice variant (rs72613567:TA) in hydroxysteroid 
17-beta dehydrogenase 13 (HSD17B13) is associated 
with a reduced risk of NASH.(11)
There is also evidence on the putative role of rare 
variants in the susceptibility of NAFLD; for instance, 
a large study in a Japanese population suggests that 
~1.79% of individuals carry rare variants potentially 
associated with NAFLD.(12) Whole-exome sequenc-
ing study on 6 Caucasian patients with extreme obesity 
(mean body mass index, 84) found two novel damaging 
mutations in Bardet-Biedl syndrome 1 (BBS1) and a 
rare damaging mutation in PNPLA3.(13)
Whether rare variants are involved in the acceler-
ated disease progression is not entirely known because 
of the lack of longitudinal studies that include patients 
with paired liver biopsies; however, significant effects 
and high penetrance would be anticipated if they were 
present. It is also uncertain whether the risk of NASH 
(the severe clinical form of NAFLD) or NASH-
cirrhosis could be associated with inherited mutations. 
While the latter appears highly unlikely, it would sup-
port the notion of NASH as a Mendelian disorder as 
well.
Patients and Methods
stuDy Design anD patient 
seleCtion
Patients were included in the study if there was his-
topathologic evidence of NAFLD, either nonalcoholic 
fatty liver or NASH, based on a liver biopsy conducted 
within the study period. Exclusion criteria were sec-
ondary causes of steatosis, including alcohol abuse 
(≥30 g alcohol daily for men and ≥20 g for women), 
total parenteral nutrition, hepatitis B and hepatitis C 
virus infection, and the use of drugs known to precip-
itate steatosis. By using standard clinical and labora-
tory evaluation as well as liver biopsy features when 
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applicable, autoimmune liver disease, metabolic liver 
disease, Wilson’s disease, and -1-antitrypsin deficiency 
were likewise ruled out in all patients.
Healthy subjects were selected for inclusion into 
the control group if their age and sex matched those 
of the patients with NAFLD and, in addition to the 
standard health assessment, a careful ultrasonographic 
examination of the liver excluded fatty liver infiltra-
tion. The case and control participants were selected 
during the same study period from the same popula-
tion of patients attending the Liver Unit, and all shared 
the same demographic characteristics.
The study involved an initial stage of exploration 
that consisted of deep sequencing of 14 chromosomal 
regions (Supporting Fig. S1) in 96 individuals, 64 of 
whom were patients with NAFLD diagnosed by liver 
biopsy and 32 were controls (Supporting Table S1). In 
addition, we performed a replication study to explore 
the presence of a rare variant in GCKR (rs149847328, 
p.Arg227Ter) that included a sample of 517 unre-
lated individuals. Patients and controls were selected 
from two different hospital-based settings, including 
a cross-sectional study of patients with NAFLD and 
metabolic syndrome (sample size n = 390) (Supporting 
Table S2) recruited in the Liver Unit, Hospital Abel 
Zubizarreta, Buenos Aires, Argentina, and an inde-
pendent cohort of patients with morbid obesity who 
underwent bariatric surgery (sample size n = 127) 
(Supporting Table S3) in the Surgery Department, 
Hospital de Alta Complejidad en Red El Cruce, 
Florencio Varela, Argentina. In the population of 
patients with morbid obesity, control subjects were 
patients with obesity who also underwent bariatric 
surgery and had no features of NAFLD demonstrated 
in the liver biopsy.
All investigations performed followed the guide-
lines of the 1975 Declaration of Helsinki. Written 
consent from individuals was obtained by the proce-
dures approved by the ethical committee of our insti-
tution (protocol numbers 104/HGAZ/09, 89/100, and 
1204/2012).
genetiC analysis
Genetic analyses were done on genomic 
DNA extracted from white blood cells.(14) Next-
generation sequencing (NGS) was performed using 
the Ion Torrent Personal Genome Machine (Life 
Technologies, Carlsbad, CA) with 316 chips and bar-
coding for >60 times coverage.(15) Library preparation 
for each sample was performed using the IT AmpliSeq 
2.0 Beta kit following the manufacturer’s instructions 
(Life Technologies). The data obtained from the Ion 
Torrent Personal Genome Machine were processed 
using the Ion Torrent Suite Software v. 4.2.1 (Life 
Technologies). Variants were annotated with the 
single-nucleotide polymorphism database (https://
www.ncbi.nlm.nih.gov/SNP/) identifications using 
SnpSift. Confirmation of the p.Arg227Ter mutation 
was performed using a TaqMan genotyping assay 
(C__33208488_10; Applied Biosystems, Foster City, 
CA).
Complete details of physical, anthropometric, and 
biochemical evaluation as well as NGS experiments, 
including variant calling, estimation of quality control, 
data analysis, and prediction of variant/mutation effect, 
are shown in the Supporting Information.
Results
Case Course anD series 
DesCription
We report on a 53-year-old male patient with 
NAFLD, arterial hypertension, morbid obesity, and 
type 2 diabetes and a family history of obesity and 
type 2 diabetes in first-degree relatives (both parents, 
two siblings, and two daughters) who developed a 
progressive histological form of the disease (NASH-
cirrhosis). Since the age of 48 (at the time of the first 
clinical consultation), the patient gained weight and 
presented persistently elevated aminotransferase lev-
els (Fig. 1A). Secondary causes of steatosis, including 
alcohol abuse, viral hepatitis, and drug-induced liver 
injury, were excluded; autoimmune liver disease, meta-
bolic liver disease, Wilson’s disease, and -1-antitrypsin 
deficiency were also ruled out. Analysis of paired liver 
biopsies (performed at baseline and follow-up, 5 years 
apart) showed liver fibrosis progression from stage F0 
to cirrhosis (Fig. 1B,C). The patient was found to be 
heterozygous CG for PNPLA3 (738409 variant) but 
homozygous CC for TM6SF2 (rs58542926 variant), 
the latter being a protective condition. In addition, 
the patient was heterozygous for the common variant 
located in GCKR rs1260326 (c.1337C>T; p.P446L), 
which has been reproducibly associated with metabolic 
traits, including NAFLD.(16)
We thus decided to search for rare variant(s) or 
mutation(s) that explain the severe clinical histological 
phenotype; we reasoned that the observed metabolic 
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Fig. 1. Clinical and histological evaluation of the patient carrying a rare mutation in the GCKR gene. Features (progressive NASH 
and difficult to manage glycemic control) show severity and extent of organ involvement. (A) Patient’s laboratory and clinical features. 
*First diagnosis of NAFLD and follow-up were 5 years apart. Serum ALT and AST (normal levels, <37 and <34 IU/L, respectively), 
GT (normal, <64 IU/L), AP (normal, <98 IU/L); #means that the patient was under insulin treatment. Results are expressed as means. 
Further laboratory features were unremarkable, including hepatitis B and C, ceruloplasmin, alpha-1-antitrypsin, and iron studies and 
antinuclear, smooth muscle, and anti-mitochondrial antibodies. Liver ultrasound showed normal liver parenchyma and biliary tree. 
Prescription medications that the patient received during the time interval of paired-biopsy evaluation were dietary, oral hypoglycemic 
medication, or insulin treatment for diabetes. Accession numbers refer to the National Center for Biotechnology Information 
Reference Sequence identification. Mutation ID + include p.Arg227Ter (forward strand of the reference sequence genome assembly) 
and p.Arg37Ter (forward strand of the curated reference sequence records, which are created by a process that includes automated 
computational methods). (B,C) Histological examination of paired liver biopsies at (B) baseline and (C) follow-up; the second follow-
up biopsy specimen was fragmented (five fragments were considered for histological assessment). Liver parenchyma shows steatosis, 
ballooned-enlarged hepatocytes, lobular inf lammation, and glycogenated nuclei. Paired histological evaluation shows the progression 
of fibrosis score from F0 to F4; histological features were assessed according to the system developed by Kleiner et al.(27) (C) Illustrated 
are nodular formation (arrow), fibrous septa-entrapping hepatocytes, portal tracts with inf lammatory infiltrate, microcirculatory 
remodeling (arrows indicate microvessels), deposition of collagen in perisinusoidal space of Disse, and pericellular fibrosis (Masson’s 
trichrome); nuclear features of hepatocyte regeneration (anisonucleosis/nuclear duplication) are also present. Histological specimens 
were assessed by a LEICA DM 2000 (Leica, Germany) trinocular microscope equipped with a high-definition camera (Leica MC190 
HD); all images were recorded using the Leica Application Suite software. Abbreviations: γGT, gamma-glutamyltransferase; alb, 
albumin; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; ExAC, 
Exome Aggregation Consortium; fpG, fasting plasma glucose; fpI, fasting plasma insulin; GN, glycogenated nuclei; GO-ESP, National 
Heart, Lung, and Blood Institute GO Exome Sequencing Project; H&E, hematoxylin and eosin stain; HbA1c, hemoglobin A1c; 
MAF, minor allele frequency; mRNA, messenger RNA; NA, not applicable; PT, portal tract; TC, total cholesterol; Ter, premature 
stop codon; TG, triglycerides; TOPMED, Trans-Omics for Precision Medicine; TRI, Masson’s trichrome stain.
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derangement could be driven by genetic diversity in 
metabolic pathways. Hence, we proceeded with the 
exploration of sequence variation by NGS of exons, 
exon–intron boundaries, and 5′ and 3′ untranslated 
regions of 14 genomic loci that encode enzymes involved 
in the regulation of metabolic processes, including the 
tricarboxylic acid (TCA) cycle, cellular respiration, and 
components of the mitochondrial matrix that control 
glutamine and glutamate metabolism. The last group 
included glutamate dehydrogenase 1 and 2 (GLUD1 
and GLUD2), glutamate-ammonia ligase (GLUL), 
glutaminase-2 (GLS2), and glutaminase (GLS). The 
list of explored loci also included isocitrate dehydro-
genases (IDH1, IDH2, IDH3A, and IDH3B) that have 
a central role in intermediary metabolism and energy 
production, as well as GCKR. Other TCA-cycle 
genes that we included in this study were aconitase-2 
(ACO2), involved in the second step of the TCA cycle, 
Fig. 2. Protein structure modeling of the p.Arg227Ter mutation in the GCKR gene. Prediction was built using the SWISS-MODEL 
resource (https://swissmodel.expasy.org/). (A) Representation of native GCKR protein and (B) mutant protein (stop gained) showing 
structural changes as the result of a premature stop codon in residue 227. A1 and B1 show amino acid sequence alignment of native 
and mutant protein, respectively. A2 and B2 show the backbone protein structure; insets highlight the effect of the p.Arg227Ter 
mutation that is responsible for a loss in the binding of a sugar (D-sorbitol-6-phosphate 9, red arrows); its binding sites involve several 
amino acids downstream of Phe226 that are then lost in the mutated protein (B2). A3 and B3 show a three-dimensional ribbon 
diagram of wild-type and mutant protein conformational structures, respectively; p.Arg227Ter truncates the protein length by about 
two thirds. A4 and B4 show representative protein expression patterns of GCKR in the liver of a patient with NASH who carries 
two copies of the wild-type (rs149847328 CC) and one copy of the mutant (rs149847328 CT) allele, respectively. A4 shows positive 
staining in more than 50% of cells; B4 shows positive staining in less than 20% of cells. Liver protein expression of GCKR was 
evaluated using immunohistochemistry; immunostaining for GCKR was performed on a subsample of six liver specimens previously 
included in paraffin (four samples of patients with NASH and similar phenotypic and clinical features of the affected patient and two 
liver specimens of the affected patient, including baseline and follow-up liver biopsies). Immunoreactivity was examined using light 
microscopy of liver sections; original magnification ×400.
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2-oxoglutarate-dehydrogenase complex (DLST), and 
malate and oxoglutarate dehydrogenases (MDH1 and 
OGDH).
Our findings revealed heterozygosity for a rare non-
sense (rs149847328 C/T, p.Arg227Ter) mutation in 
the GCKR gene, the frequency of which is 0.0003963 
in the Exome Aggregation Consortium database 
(4:10,000; 48 of 121,126 alleles). The GCKR mutation 
was further confirmed using a TaqMan genotyping 
assay (C__33208488_10; Applied Biosystems).
The substitution of a C with a T converts the arginine 
codon to a premature stop codon (Fig. 1A), resulting 
in the protein transcribed from the mutant messenger 
RNA being incomplete (Fig. 2A,B). Previous in vitro 
mutagenesis experiments confirmed that p.Arg227Ter 
truncates the protein length by about two thirds.(17)
As expected, GCKR protein expression was mark-
edly decreased in the liver of the affected patient 
compared with patients with NAFLD carrying the 
wild-type allele (Fig. 2A,B).
In addition, we deep sequenced the same chro-
mosomal regions in 95 individuals, of whom 63 were 
patients with NAFLD diagnosed by liver biopsy and 32 
were controls, and we failed to reveal the rare mutation. 
A more extensive screening by a TaqMan assay was car-
ried out in a cross-sectional case-control study involv-
ing a sample of 517 individuals, including patients who 
were morbidly obese. The results confirmed the rarity 
of p.Arg227Ter because neither the controls nor the 
patients were found to carry the mutation.
Discussion
Common variants in the GCKR gene are associ-
ated with alterations in metabolic traits, including 
NAFLD(16,18) and plasma triglyceride levels.(19) The 
gene product is a regulatory protein that inhibits glu-
cokinase (GCK, hexokinase 4) in the liver and pan-
creatic islet cells by binding noncovalently to form 
an inactive complex with the enzyme. The affinity of 
GCKR for GCK is modulated by fructose metabolites; 
GCKR with bound fructose 6-phosphate has increased 
affinity for GCK, while GCKR with bound fructose 
1-phosphate has strongly decreased affinity for GCK 
and does not inhibit GCK activity.(20) The GCKR-p.
Arg227Ter variant abolishes two fructose 1-phosphate 
sites (positions 348 and 514); likewise, mutant protein 
lacks domains that are essential for interaction with 
GCK (Fig. 2B).
GCKR is considered a susceptibility gene for a form 
of maturity-onset diabetes of the young (https://www.
omim.org/entry/600842) and familial clustering of 
type 2 diabetes.(21,22) In addition, cosegregation anal-
ysis of obesity and the GCKR-p.Arg227Ter mutation 
has been elegantly assessed by Veiga-da-Cunha and 
coworkers,(17) who initially described the presence of 
the stop codon in five of six members of an obese fam-
ily. While it was suggested that p.Arg227Ter does not 
necessarily predispose to obesity,(17) it was shown that 
GCK activity is decreased by about 50% in subjects 
with obesity and diabetes who carry the mutation.(23)
The patient we present here not only carries the 
p.Arg227Ter mutation but also developed a complex 
phenotype clustering morbid obesity, type 2 diabe-
tes, and NASH, the later condition associated with 
impaired hepatic glucose metabolic machinery ren-
dering the organ prone to rapidly progressive severe 
damage.
To our knowledge, this is the first report on the 
role of a rare GCKR mutation in the susceptibility of 
the NASH phenotype; heterozygosity for the GCKR 
mutation may explain onset of the disease in adult-
hood. In addition, due to the critical role of GCKR in 
modulating hepatic glucose and lipid metabolism, it is 
expected that mutations in this gene may have a signif-
icant impact in the phenotype even in the heterozygote 
state.(24) This observation is supported by phenotypic 
characterization of GCKR-knockout mice that showed 
that both heterozygote (+/–) and homozygote (–/–) 
mice present a substantial decrease in hepatic GCK 
expression and enzymatic activity when compared with 
wild-type mice and fail in a glucose tolerance test to 
sustain appropriate glucose clearance.(23,25)
Some limitations of our study should be high-
lighted; specifically, the patient’s phenotype cannot 
be fully ascribed to the presence of the p.Arg227Ter 
mutation because other variants/mutations not tested 
in this study might be involved in the course of the dis-
ease. Furthermore, we cannot rule out that other non-
genetic factors might have modulated the accelerated 
course of the disease, including poor glucose control or 
the presence of morbid obesity. It is known that adi-
posity increases the genetic risk of NAFLD at multiple 
loci that predispose to the disease.(26) Finally, it would 
have been particularly informative having information 
on the p.Arg227Ter mutation in family members of 
the proband; unfortunately, family members opted not 
to take part in the genetic testing. Therefore, phasing 
with other variants was not possible.
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In conclusion, while rare variants/mutations are 
difficult to detect in even reasonably large samples, 
the presence of this mutation should be suspected as 
potentially associated with NAFLD, particularly in 
young adults at the extreme of histological phenotypes.
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